Sevoflurane

CAS No:
28523-86-6 Category:
  • #LGM Pharma is a Sevoflurane CAS# 28523-86-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 28523-86-6
  • AHFC code: 28:04.0
  • Synonyms: Sevofluran Sevoflurano [INN-Spanish] Sevofluranum [INN-Latin]
  • ATC Code: N01AB08
  • Chemical Formula: C25H38O5
  • Molecular Weight: 200.0548
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01236 (APRD00219)
  • SMILES: FCOC(C(F)(F)F)C(F)(F)F
  • InChl: DFEYYRMXOJXZRJ-UHFFFAOYSA-N
  • PubChem: 5206
  • IUPAC: 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane

Additional Details

Indication:
Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Pharmacodynamics:
Sevoflurane (also called fluoromethyl) is a halogenated ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. It is often administered in nitrous oxide and pure oxygen. After desflurane it is the volatile anesthetic with the fastest onset and offset. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mode of Action:
Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor, and the glycine receptor.
Metabolism:
Relatively little biotransformation, only 5% is metabolized by cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. No other metabolic pathways have been identified for sevoflurane.
Toxicity:
LC50=49881 ppm/hr (rat), LD50=10.8 g/kg (rat)
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos